Analysis of the effect of iodine 131 combined with thyroid hormone after thyroid cancer surgery.

Clinical data of 196 patients with thyroid cancer admitted to our hospital between June 2016 and July 2019 were retrospectively analyzed. According to different postoperative treatment options, the patients were divided into two groups: the combined group (n=98) was treated with iodine 131 combined with thyroid hormone during the perioperative period; the conventional group (n=98) was treated with thyroid hormone during the perioperative period. Spsss23.0 statistical software was used to process the data. The positive expression rate of tumor related factors, breast cancer metastasis suppressor gene 1 (BRMSl) and gap junction protein 43 (Cx43) in the two groups were expressed by (±s), and independent t test was used; the count data of residual thyroid tissue clearance rate was tested by χ² test; P<0.05 was statistically significant.

The clearance rate of residual thyroid tissue in the combined group (62.2%) was higher than that in the conventional group (46.9%), and the expression of p53, Fas and TNF-α was higher than that in the conventional group (P<0.05). The positive expression rates of breast cancer metastasis suppressor gene 1 (BRMSl) and cell gap junction protein 43 (Cx43) in the combination group were 92.9% and 94.9%, respectively, higher than those in the conventional group, 81.6% and 80.6%, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Treatment of thyroid cancer patients with iodine 131 combined with thyroid hormone can increase the positive rate of BRMS1 and Cx43 protein expression and promote the removal of residual thyroid tissue. It has high clinical value and is worthy of application.